# Perioperative Outcomes of Robotic Radical Prostatectomy with Hugo™ RAS versus daVinci Surgical Platform: Propensity Score-Matched Comparative Analysis

**Authors:** Carlo Gandi, Filippo Marino, Angelo Totaro, Eros Scarciglia, Fabrizio Bellavia, Riccardo Bientinesi, Filippo Gavi, Pierluigi Russo, Mauro Ragonese, Giuseppe Palermo, Marco Racioppi, Nicolò Lentini, Roberta Pastorino, Emilio Sacco

PMC · DOI: 10.3390/jcm13113157 · Journal of Clinical Medicine · 2024-05-28

## TL;DR

This study compares the outcomes of robotic prostate surgery using two different systems and finds no significant differences in key measures.

## Contribution

The study provides a direct comparison of two robotic surgical platforms using propensity score matching.

## Key findings

- No significant differences were found in positive surgical margins between the two robotic systems.
- Perioperative outcomes like operative time and blood loss were similar for both platforms.
- Surgeons can effectively transfer their proficiency from daVinci to Hugo™ RAS systems.

## Abstract

Background/Objectives: There is an urgent need for comparative analyses of the intraoperative, oncological, and functional outcomes of different surgical robotic platforms. We aimed to compare the outcomes of RARP performed at a tertiary referral robotic centre with the novel HugoTM RAS system with those performed with a daVinci surgical system, which is considered the reference standard. Methods: We analysed the data of 400 patients undergoing RARP ± pelvic lymph node dissection between 2021 and 2023, using propensity score (PS) matching to correct for treatment selection bias. All procedures were performed by three surgeons with HugoTM RAS or daVinci. Results: The PS-matched cohort included 198 patients with 99 matched pairs, balanced for all covariates. Positive surgical margins (PSMs) were found in 22.2% and 25.3% (p = 0.616) of patients, respectively, in the HugoTM RAS and daVinci groups. No significant differences were found for other important perioperative outcomes, including median (1st–3rd q) operative time (170 (147.5–195.5) vs. 166 (154–202.5) min; p = 0.540), median (1st–3rd q) estimated blood loss (EBL) (100 (100–150) vs. 100 (100–150) ml; p = 0.834), Clavien–Dindo (CD) ≥ 2 complications (3% vs. 4%; p = 0.498), and social continence at 3 months (73.7% vs. 74.7%; p = 0.353). In multiple analyses, no associations were found between surgical outcomes (PSM, length of PSM, operative time, EBL, length of catheterization, length of hospital stay, social continence at three months after surgery, and CD ≥ 2 complications) and the robotic platform. Conclusions: Our findings demonstrate that HugoTM RAS enables surgeons to safely and effectively transfer the level of proficiency they reached during their previous experience with the daVinci systems.

## Linked entities

- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11173080/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11173080/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC11173080/full.md

---
Source: https://tomesphere.com/paper/PMC11173080